Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Indacaterol Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 334,644Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis to present new findings of Enerzair Breezhaler at ERS congress
    Novartis to present new findings of Enerzair Breezhaler at ERS congress

    06 Sep 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=142343&sid=2

    PHARMABIZ
    06 Sep 2021
    Share Share
    High-dose Enerzair Breezhaler further cuts asthma exacerbations
    High-dose Enerzair Breezhaler further cuts asthma exacerbations

    07 Sep 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/high-dose_enerzair_breezhaler_further_cuts_asthma_exacerbations_1348771

    Selina McKee PHARMATIMES
    07 Sep 2020
    Share Share
    Novartis phase III IRIDIUM study show reduced severe asthma exacerbation rates
    Novartis phase III IRIDIUM study show reduced severe asthma exacerbation rates

    07 Sep 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130923&sid=2

    PHARMABIZ
    07 Sep 2020
    Share Share
    Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show of Enerzair®
    Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show of Enerzair®

    10 Jul 2020

    // PRESS RELEASE

    https://www.novartis.com/news/media-releases/novartis-phase-iii-iridium-data-lancet-respiratory-medicine-show-benefit-enerzair-breezhaler-qvm149-first-class-inhaled-labalamaics-combination-uncontrolled

    PRESS RELEASE
    10 Jul 2020
    Share Share